Regeneron said the rejection was 'solely due to an ongoing review of inspection findings at a third-party filler.'
The company was seeking approval for an 8-milligram dose of its injection, Eylea, for patients with wet age-related macular degeneration — the leading cause of blindness among the elderly — and two other eye diseases that are common in people with diabetes.
Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler." The company did not provide further details on those findings or identify the third party, but said the decision was not related to the drug's efficacy, safety, trial design, labeling or drug substance manufacturing.But a delay won't help the company fight off threats to its Eylea drug franchise, which is facing competition fromRegeneron stock fell nearly 9% Tuesday after an FDA rejection of a higher-dose version of the company's blockbuster eye treatment.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FDA approves 1st treatment that can grow back hair for teens with severe alopecia areataMarking a historic first, the FDA has approved an alopecia treatment for kids 12 and over.
続きを読む »
Hydration nation: Clients clamor for IV therapy on demand even though it’s not FDA-approvedAre IV therapy 'bars' and stations worth all the hype? Fox News Digital spoke to multiple experts about the benefits and risks of these on-demand hydration facilities.
続きを読む »
Dublin family celebrates FDA approval of gene therapy for Duchenne developed in Central Oh'It is huge. It’s going to change the course of this disease,' said Dublin mom Amber Nisley. 'I mean, it truly is a game changer. This has never happened before
続きを読む »
AC Immune’s stock soars 13% after FDA grants fast-track designation to Alzheimer’s treatmentAC Immune SA’s stock soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track...
続きを読む »
Thousands of unauthorized vapes are pouring into the US despite the FDA crackdown on fruity flavorsThe trend underscores the FDA’s inability to control the tumultuous vaping market previously dominated by Juul and other reusable e-cigarettes.
続きを読む »